Prevalence and management of hypertension in patients with acute coronary syndrome vary with gender: Observations from the Chinese registry of acute coronary events (CRACE)

• Published in: Molecular medicine reports Vol. 8; no. 1; pp. 173 - 177
• Main Authors: LIN, YUN, PAN, WEIQI, NING, SHANGQIU, SONG, XIANTAO, JIN, ZENING, LV, SHUZHENG
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.07.2013; Spandidos Publications UK Ltd
• Subjects: Acute Coronary Syndrome - complications; Acute coronary syndromes; Adult; Age; Age Factors; Aged; Aged, 80 and over; Angina pectoris; Angiotensin; Angiotensin-converting enzyme inhibitors; Antihypertensive Agents - therapeutic use; Antihypertensives; Blood pressure; Calcium; Cardiovascular disease; Coronary vessels; Demographics; Diabetes; Disease Management; Diuretics; Enzymes; Family medical history; Female; Gender; Health risk assessment; Heart attacks; Heart failure; Hospital Mortality; Humans; Hypertension; Hypertension - complications; Hypertension - drug therapy; Hypertension - epidemiology; Male; Middle Aged; Mortality; Patients; Peptidyl-dipeptidase A; Prevalence; Registries; Risk Factors; sex; Sex Factors; Statistical analysis; Stroke; Treatment Outcome; Women; Young Adult; β-blockers; China
• ISSN: 1791-2997; 1791-3004
• DOI: 10.3892/mmr.2013.1461

Hypertension affects one billion people worldwide and is an independent risk factor for death after acute coronary syndrome (ACS). The aim of this study was to examine the prevalence and medical treatment of hypertension among 1,301 ACS patients enrolled into the Chinese registry of acute coronary events (CRACE) trial. Analyses were performed by gender, with both genders combined and according to international practice. Multivariable models identified factors associated with use of different classes of antihypertensive medication, and examined the correlation between hypertension and gender with mortality. The use of angiotensin-converting enzyme inhibitors (ACEI), β-blockers, calcium channel blockers (CCBs) and diuretics increased in both genders during management of presenting ACS. Hypertensive men were more likely to have been receiving β-blockers when they were discharged (77.2%) than women (69.2%). Hypertensive women were more likely to have received diuretics when they were discharged (28.4%) than men (22%). ACEI use increased by ~60% (absolute increase) in both women and men as a result of ACS treatment, but remained similar between the genders, and the same phenomenon was observed in the use of CCBs. Moreover, hypertensive women were less likely to receive evidence-based medication to treat their acute coronary event than men (for women and men, respectively: β-blocker, 69.2 vs. 77.2%; ACEI, 85.8 vs. 87.5%). Hypertension is more prevalent in women than in men with ACS, and its medical management varies with gender, but it has a similar association with mortality in both genders. Opportunities exist to improve medical therapy and outcomes for women with hypertension.